Jazz Pharmaceuticals To Present Long-Term And Real-World Data Emphasizing Commitment To Treatment-Resistant Epilepsy At The 2023 American Epilepsy Society Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Jazz Pharmaceuticals (NASDAQ:JAZZ) will present data from nine abstracts at the 2023 American Epilepsy Society Annual Meeting, emphasizing its commitment to treatment-resistant epilepsy. The presentations will include real-world outcomes of Epidiolex (cannabidiol) in treatment-resistant focal epilepsies and data on caregiver-reported outcomes in patients with tuberous sclerosis complex (TSC) prescribed Epidiolex. The data suggests sustained reduction in focal-onset seizures and improvements in cognition, emotional functioning, and communication in patients. The Expanded Access Program (EAP) and GWPCARE6 Open-Label Extension (OLE) trial results will also be shared.
December 01, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jazz Pharmaceuticals is set to present promising data on Epidiolex for treatment-resistant epilepsy at the AES Annual Meeting, which may positively influence perceptions of the drug's efficacy and its potential market.
The presentation of positive data from multiple studies on Epidiolex at a major conference could lead to increased physician interest and potentially higher prescription rates, which would have a positive short-term impact on Jazz Pharmaceuticals' stock. The focus on real-world outcomes and the inclusion of caregiver-reported data may enhance the drug's profile in the medical community and among patients, potentially leading to increased sales.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100